PMID- 38153672
OWN - NLM
STAT- MEDLINE
DCOM- 20240104
LR  - 20240221
IS  - 2212-5469 (Electronic)
IS  - 1738-2696 (Print)
IS  - 1738-2696 (Linking)
VI  - 21
IP  - 1
DP  - 2024 Jan
TI  - Long and Short-Term Effect of mTOR Regulation on Cerebral Organoid Growth and 
      Differentiations.
PG  - 159-169
LID - 10.1007/s13770-023-00611-3 [doi]
AB  - BACKGROUND: The mammalian target of rapamycin (mTOR) signaling is critical for 
      the maintenance and differentiation of neurogenesis, and conceivably for many 
      other brain developmental processes. However, in vivo studies of mTOR functions 
      in the brain are often hampered due to the essential role of the associated 
      signaling in brain development. METHODS: We monitored the long- and short-term 
      effects of mTOR signaling regulation on cerebral organoids growth, 
      differentiation and function using an mTOR inhibitor (everolimus) and an mTOR 
      activator (MHY1485). RESULTS: Short-term treatment with MHY1485 induced faster 
      organoid growth and differentiation, while long-term treatment induced the 
      maturation of cerebral organoids. CONCLUSION: These data suggest that the optimal 
      activity of mTOR is crucial in maintaining normal brain development, and its role 
      is not confined to the early neurogenic phase of brain development.
CI  - (c) 2023. Korean Tissue Engineering and Regenerative Medicine Society.
FAU - Park, Sung Bum
AU  - Park SB
AD  - Therapeutics and Biotechnology Division, Korea Research Institute of Chemical 
      Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea.
FAU - Lim, Byungho
AU  - Lim B
AD  - Therapeutics and Biotechnology Division, Korea Research Institute of Chemical 
      Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea.
FAU - Kim, Ki Young
AU  - Kim KY
AD  - Therapeutics and Biotechnology Division, Korea Research Institute of Chemical 
      Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea. 
      kykim@krict.re.kr.
FAU - Koh, Byumseok
AU  - Koh B
AUID- ORCID: 0000-0002-1106-1891
AD  - Therapeutics and Biotechnology Division, Korea Research Institute of Chemical 
      Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, Republic of Korea. 
      bkoh@krict.re.kr.
LA  - eng
GR  - 2021R1A2C2011195/Ministry of Science and ICT/
GR  - 20009774/Ministry of Trade, Industry and Energy/
GR  - KK2331-40/Korea Research Institute of Chemical Technology/
PT  - Journal Article
DEP - 20231228
PL  - Korea (South)
TA  - Tissue Eng Regen Med
JT  - Tissue engineering and regenerative medicine
JID - 101699923
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Everolimus
MH  - Organoids/metabolism
MH  - Signal Transduction
MH  - *Sirolimus/pharmacology
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Brain/growth & development
PMC - PMC10764682
OTO - NOTNLM
OT  - Cerebral organoids
OT  - Differentiation
OT  - Growth
OT  - mTOR regulation
COIS- The authors have no potential conflict of interest.
EDAT- 2023/12/28 12:41
MHDA- 2024/01/04 11:43
PMCR- 2024/12/28
CRDT- 2023/12/28 11:26
PHST- 2023/08/03 00:00 [received]
PHST- 2023/10/29 00:00 [accepted]
PHST- 2023/09/20 00:00 [revised]
PHST- 2024/12/28 00:00 [pmc-release]
PHST- 2024/01/04 11:43 [medline]
PHST- 2023/12/28 12:41 [pubmed]
PHST- 2023/12/28 11:26 [entrez]
AID - 10.1007/s13770-023-00611-3 [pii]
AID - 611 [pii]
AID - 10.1007/s13770-023-00611-3 [doi]
PST - ppublish
SO  - Tissue Eng Regen Med. 2024 Jan;21(1):159-169. doi: 10.1007/s13770-023-00611-3. 
      Epub 2023 Dec 28.